ClinicalTrials.gg
RecruitingNCT05043948GWAScollateralUpdated Sep 14, 2021

Genome-wide Association Study of Development of Collateral Circulation for Patients With Coronary or Peripheral Artery Disease

An observational study in Coronary Disease, Peripheral Arterial Disease and Collateral Circulation, Any Site, sponsored by Jung-min Ahn. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by Jung-min Ahn · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2015; still recruiting 11 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Coronary Disease with a site in Korea, Republic of — 6 open to participants now, 7 under way, none of them phase 3. Coronary Disease · Korea, Republic of.

Planned enrollment
14th of 20
400 · median 1,125
Started
2015
with 2 others
Observational
20 of 49
4 open now
Registered
46th of 49
by date
Lead sponsor
3 of 49
Jung-min Ahn

Among the 49 studies in Coronary Disease with a site in Korea, Republic of, this one is the 14th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2015, is one of 20 observational ones, and was the 46th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

6 of the 49 studies in Coronary Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Coronary Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the genome-wide association for the development of collateral circulation for patients with coronary or peripheral artery disease and to develop the molecular genetic treatment model based on genome-wide association data.

03

Conditions studied

  • Coronary Disease
  • Peripheral Arterial Disease
  • Collateral Circulation, Any Site

Keywords

  • Genome-wide association
  • Collateral circulation
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic total coronary or peripheral occlusion

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age more than 20
  • Chronic total occlusive lesion from the coronary or peripheral angiogram

Exclusion criteria

Exclusion Criteria:

  • Renal dysfunction
  • Hepatic dysfunction
  • Thrombocythemia or thrombocythemia
  • Planned major surgery in 1 year
  • History of gastrointestinal haemorrhage
  • Malignant tumor
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Coronary Artery Disease_collateral flow grade 2

    Diagnostic Test: Blood samples

  • Coronary Artery Disease_collateral flow grade 0

    Diagnostic Test: Blood samples

  • Peripheral Artery Disease_collateral flow grade 2

    Diagnostic Test: Blood samples

  • Peripheral Artery Disease_collateral flow grade 0

    Diagnostic Test: Blood samples

Interventions

  • Diagnostic testBlood samples

    for evaluation of the genome-wide association study

06

What researchers measure

Primary outcomes

  1. Correlation between genome and collateral flow

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2015 (actual). Primary completion is estimated for Jun 2025, 118 months after the start.

Of 132 non-industry observational studies under Coronary Disease, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's planned 118 months is above that.

Counting every sponsor, half of 154 studies reached it within 47 months; a quarter within 21 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2021
First posted
Sep 14, 2021
StartActual
Aug 21, 2015
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05043948
Lead sponsor
Jung-min Ahn
Responsible party
Jung-min Ahn (Assistant Professor, Asan Medical Center) — Sponsor-investigator
First posted
Sep 14, 2021
Start date
Aug 21, 2015
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 14, 2021

Study contacts

Jung-hee Ham, Project manager
Contact
cvcrc5@amc.seoul.kr
82230104728

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion